50 filings analyzed. Top movers: RAPID MICRO BIOSYSTEMS, INC., Corvex, Inc., Childrens Place, Inc., EAGLE FINANCIAL SERVICES INC, AIR INDUSTRIES GROUP.
8-K
RAPID MICRO BIOSYSTEMS, INC.
Rapid Micro Biosystems signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany via tender offer (share count and price undisclosed in this filing). Q3 2026 revenue grew 22% to $9.5M with gross margin expanding to 25% (from 9% YoY), but the company remains unprofitable: net loss $11.3M, with ~$7M cash on hand and $19.2M notes payable outstanding. CEO stated 18-month prior partnership with Merck underpins deal rationale.
▲ Likely positive
· significance 95 · 8-K Agent
8-K
Corvex, Inc.
Corvex signed a 3-year, $103M take-or-pay agreement with an unnamed scaled AI inference platform to provide NVIDIA Blackwell GPU capacity at its Mid-Atlantic 1 data center. The ~$78M deployment (1,000+ HGX B200 GPUs, 1.6 MW IT capacity) is 80% funded by $26M customer prepayment and $38M non-recourse debt from USD.AI; Corvex funds remaining $14M. Mid-Atlantic 1 contracted ARR increases from $22M to ~$56M upon full deployment in Q1 2027; this is Corvex's third Blackwell deployment at that site.
▲ Likely positive
· significance 94 · 8-K Agent
8-K
Childrens Place, Inc.
Children's Place, Inc. obtained a $166 million senior secured debtor-in-possession asset-based revolving credit facility (the DIP Facility) dated November 10, 2026, led by Wells Fargo Bank. The facility supports the company's Chapter 11 bankruptcy cases filed November 8, 2026 (Case Nos. 26-22682 through 26-22695). Key terms: 3.50% applicable margin, $20M letter of credit sublimit, $16M Canadian revolving credit ceiling, maturity January 29, 2027. The DIP supersedes the company's prepetition credit agreement and is secured by substantially all collateral with superpriority claims subject only to carve-out allowances for professional fees and certain Canadian priority charges.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
EAGLE FINANCIAL SERVICES INC
Eagle Financial Services (EFSI, $152.5M market cap) received Federal Reserve approval on November 16, 2026, to merge Bank of Clarke into John Marshall Bank, with shareholder votes scheduled for November 19, 2026. The deal, announced September 8, 2026, combines EFSI's $1.9B in assets with John Marshall's $2.4B to create a $4.3B combined entity. Transaction remains subject to Virginia Bureau of Financial Institutions approval and customary closing conditions.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
AIR INDUSTRIES GROUP
Air Industries Group (market cap ~$10M) will hold a special stockholder meeting on November 18, 2026, to vote on merger with Tenax Aerospace Acquisition LLC. Current AIR shareholders will own ~4% post-merger on fully diluted basis; Tenax member Thomas Foley will own ~52%. Tenax generated $133.4M revenue in 2025; merger will fund repayment of AIR's ~$26.1M debt, and AIR shareholders receive non-transferable redemption rights at ~$3.27/share (pre-split) on first anniversary.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
CYABRA, INC.
Cyabra Inc. issued 45,611 shares of Series D Convertible Preferred Stock with a stated value of $1,000/share ($45.6M total) plus warrants, in an initial closing for $15.61M ($10M cash + $5.61M debt conversion). The preferred stock converts at $0.15/share, pays 6% annual cumulative dividends, and comes with 1:1 warrant coverage. Lead investor is Alpha Capital Anstalt. Company has $2.6M in total assets; this financing is 600% of company size.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
AYTU BIOPHARMA, INC
On November 16, 2026, Aytu BioPharma entered a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc., whereby Rosemont will acquire Aytu through a cash tender offer at $2.70 per share, representing approximately $56 million on a fully-diluted basis. The transaction is expected to close by end of calendar 2026, subject to majority shareholder tender and customary closing conditions. Q1 FY2027 results showed net revenue of $14.8M (up 6.9% YoY), EXXUA revenue of $4.9M (up 24.5% sequentially), but net loss of ($3.9)M vs. prior-year net income of $2.0M, with cash declining to $25.5M from $26.3M.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
AETHLON MEDICAL INC
Aethlon Medical (AEMD, $5.7M market cap) is combining with North Immunology via business combination where North becomes a wholly owned subsidiary of AEMD. Concurrent private placement of $180M (inclusive of $34M convertible note) will be raised. Post-closing capitalization: AEMD 4.75%, North 43.17%, PIPE investors 52.08% (71.2M total shares). North's lead asset NOR-101 is a half-life extended anti-IL-13 × IL-18 bispecific antibody targeting atopic dermatitis, with Phase 1a planned Q1 2027.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
Hyperscale Data, Inc.
Hyperscale Data announced preliminary unaudited Q3 2026 revenue of approximately $44.8 million, representing 84% growth versus $24.3 million in Q3 2025, and exceeding prior guidance of $40 million by 12%. The company also announced plans to divest subsidiary Ault Capital Group (ACG) in 2027 through exchange of Series F Preferred Stock issued December 23, 2024 to common stockholders and Series C Preferred holders.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (total assets ~$5.0M) filed an 8-K on 2026-11-16 disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific details regarding which exchange issued the notice, the reason for non-compliance, timeline for cure, or any remediation plan. Only the fact of the delisting notice is disclosed; financial impact and next steps are not specified in this document.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
XMax Inc.
XMax Inc. filed an 8-K on 2026-11-16 disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing provides no specific details regarding which exchange issued the notice, the specific listing rule violation, cure periods, or remedial actions. The bare-bones disclosure lacks material specifics about timing, conditions, or company response.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Cable One, Inc.
On November 13, 2026, Cable One received notice from NYSE that it failed continued listing standards: average global market capitalization over 30 trading days fell below $50M AND stockholders' equity fell below $50M. The company has 45 days to submit a compliance plan and 18 months to cure; delisting proceedings could follow if the plan is rejected or not submitted timely. The notice does not immediately affect listing or operations, but failure to cure could force delisting.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Greenlane Holdings, Inc.
Greenlane Holdings (market cap ~$1M) transitioned to a digital asset treasury strategy in October 2025, funded by a $110.7M private investment. As of September 30, 2026, the company held 85.8M BERA tokens (fair value $21.8M, cost basis $80.4M) versus 60.4M at year-end 2025. Q3 2026 net income was $4.4M (including $4.5M non-cash fair value gain and $3.1M deconsolidation gain); current liabilities dropped to $3.2M from $6.5M in June 2026. However, BERA's price collapsed 55% post-quarter (from $0.25 to $0.11 by Nov 13), eroding digital asset value to ~$8.5M by Nov 16; cash of $1.1M plus $8.1M stablecoins covers only ~12 months' needs. The company faces imminent Nasdaq delisting if market value stays below $5M (pending SEC rule review) and substantial going-concern doubt.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
ENDRA Life Sciences Inc.
ENDRA announced it is advancing a proposed merger with Noble Africa LLC (ASP Isotopes subsidiary), announced June 25, 2026, whereby Noble Africa becomes ENDRA's wholly owned subsidiary and ENDRA is renamed 4K Resources Inc. The deal includes a concurrent $50 million private placement into Noble Africa and contribution of ASP Isotopes' Renergen Limited stake. Transaction remains subject to stockholder approval, S-4 effectiveness, and Nasdaq compliance. Q3 2026: cash burn was $1.8M (vs. $1.2M in Q3 2025), net loss $1.5M; as of Sept 30, 2026, unrestricted cash was $1.5M, restricted cash $3.4M, digital assets $1.3M.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
GALECTIN THERAPEUTICS INC
On July 31, 2026, Galectin's Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 shares of common stock, eliminating five of six credit facilities and strengthening the balance sheet. Concurrently, the company submitted a registrational Phase 3 protocol to FDA for belapectin in MASH cirrhosis with portal hypertension (primary endpoint: composite liver outcome); NAVIGATE Phase 2b/3 data presented at AASLD showed belapectin-treated patients had 15.9% placebo-adjusted improvement in ANTICIPATE-NASH CSPH risk (p=0.04). Q3 2026 cash position: $11.7M with $10M additional credit line available; company projects funding through June 2027.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Adagio Medical Holdings, Inc.
Adagio Medical (market cap ~$7M) reported Q3 2026 with zero revenue, operating losses of $4.4M, and cash of $3.1M (down from $17.1M at year-end 2025). A $23M noncash gain from convertible note fair-value revaluation drove reported net income of $17.8M, but diluted EPS was negative $5.13. The Board initiated a formal process to explore strategic alternatives. The company effected a 1-for-30 reverse stock split on November 6, 2026 to regain Nasdaq compliance. Clinical progress includes 22 patients treated with vCLAS Ultra System and ongoing FDA PMA review.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
CG Oncology, Inc.
CG Oncology announced positive topline results from PIVOT-006, a Phase 3 trial of cretostimogene in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The drug achieved a 68% reduction in recurrence risk (hazard ratio 0.32, 95% CI 0.23–0.45, p<0.0001) versus surveillance in 367 patients, with no Grade 3+ treatment-related adverse events. A second BLA submission for this indication is planned for Q2 2027; the company also plans to expand its first BLA (BCG-unresponsive NMIBC) to include high-grade papillary-only disease, completing submission by March 2027.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
John Marshall Bancorp, Inc.
John Marshall Bancorp (JMSB, $231.6M market cap) and Eagle Financial Services (EFSI) received Federal Reserve approval on November 16, 2026, to merge Bank of Clarke into John Marshall Bank. The all-stock transaction, announced September 8, 2026, combines John Marshall's $2.4B in assets with EFSI's $1.9B in assets to create a $4.3B combined entity. Shareholder votes are scheduled for November 19, 2026; closing remains subject to Virginia state banking approvals and customary conditions.
▲ Likely positive
· significance 78 · 8-K Agent
10-Q
Boxlight Corp
On Nov 10, 2026, Boxlight received a forbearance agreement from lender Whitehawk Capital Partners LP waiving multiple Events of Default: over-advances vs. permitted borrowing base in Aug-Oct 2026, and financial covenant failures across 8-10 fiscal months. The company also extended its inventory finance agreement with J.J. Astor Co. by one year (Nov 3, 2027) and increased authorized shares to 600M (500M Class A, 50M Class B, 50M Preferred) via stockholder vote Nov 10, 2026. Specific dollar amounts of defaults and over-advances are not disclosed.
▼ Likely negative
· significance 78 · Periodic Agent
SCHEDULE 13D
AQUABOUNTY TECHNOLOGIES INC
On April 7, 2026, Bradley Richmond and Univest Securities LLC exchanged senior notes totaling $1.475M ($225K + $1.25M principal plus accrued interest) for 78,297 shares of Series A Convertible Preferred Stock. On October 23, 2026, these preferred shares automatically converted to 1,681,096 common shares at $0.9129/share. Additionally, Bradley Richmond made numerous open-market common stock purchases April–August 2026 totaling ~89K shares at prices ranging $0.87–$0.97/share.
▲ Likely positive
· significance 78 · Ownership Agent
SCHEDULE 13D/A
Neuronetics, Inc.
Between 10/30/2026 and 11/13/2026, an identified reporting person executed a net sale of approximately 8,515,362 shares of Neuronetics common stock. Share prices declined sharply from $2.27 (10/30) to $1.16 (11/13), a 49% drop. The largest single transaction was a sale of 7.4M shares on 11/13/2026 at $1.16/share, suggesting either forced liquidation or a major shareholder exit.
▼ Likely negative
· significance 76 · Ownership Agent
8-K
Stewards, Inc.
Stewards (Nasdaq: SWRD), a $174M-asset company, completed a $79M refinancing of property 1818 Park on July 24, 2026, and acquired Envy Pompano Beach on September 23, 2026. Total assets grew 49% to $265.3M; however, Q3 net loss widened to $19.4M (vs. $6.4M YoY) and revenue declined to $3.4M (vs. $5.3M YoY). The company disclosed substantial-doubt-about-going-concern conditions (missed Envy redemption payments, unpaid interest, near-term debt maturities), which management's board-approved restructuring plans are intended to mitigate. Post-quarter, Stewards secured $31.8M noteholder waivers/standstill, restructured the $21M Envy redemption into preferred shares, and raised $4.9M net proceeds via a convertible note.
▼ Likely negative
· significance 76 · 8-K Agent
8-K
Toppoint Holdings Inc.
Toppoint Holdings (market cap ~$6.9M) reported Q3 2026 revenue of $4.5M (flat YoY), with nine-month revenue of $13.3M (up 8.1%). However, gross margin collapsed to 12% in Q3 (from 17% YoY) and net loss was $1.1M for nine months. NYSE American halted trading on November 10, 2026 due to low stock price; the board approved a 1:5 reverse stock split effective ~November 23, 2026. Cash position is $4.8M; the company has a $5M loan receivable with $500K collected and $1.5M expected by year-end.
▼ Likely negative
· significance 76 · 8-K Agent
8-K
Ocean Power Technologies, Inc.
Ocean Power Technologies announced pricing of a $3.0 million public offering on a best-efforts basis, comprising 6,000,000 shares of common stock and warrants to purchase 6,000,000 additional shares at $0.50/share expiring in 5 years. D. Boral Capital LLC serves as exclusive placement agent. Closing expected November 16, 2026, with gross proceeds of $3.0 million before placement agent fees.
▼ Likely negative
· significance 73 · 8-K Agent
10-Q
GoPro, Inc.
GoPro issued two senior secured notes on July 9, 2026: $5M to Terrapin Trust (6.5% interest, maturing July 21, 2028) and $15M to Woodman Family Trust (same terms). Both notes are third-lien secured obligations subordinate to Wells Fargo (first lien) and Farallon Capital (second lien). Concurrent warrants grant holders rights to purchase ~25.7M Class B shares at $0.778/share, exercisable from January 9, 2027 or upon change of control. Proceeds fund payables to suppliers.
▼ Likely negative
· significance 73 · Periodic Agent
8-K
Silexion Therapeutics Corp
Silexion dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on September 30, 2026. Q3 2026 financings (public offering ~$2.5M, warrant inducement ~$0.84M, ATM ~$1.9M) increased cash to $4.8M and shareholders' equity to $3.0M as of September 30, 2026. New preclinical data showed immune-sensitization across four KRAS mutations and lipoprotein-mediated uptake mechanism; nine-month net loss was $8.8M.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Aclaris Therapeutics, Inc.
Aclaris announced on November 16, 2026 that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody for atopic dermatitis, did not achieve primary or secondary endpoints, though pharmacodynamic data showed robust target engagement. The company is refocusing development on modzatinib (ITK/JAK3 inhibitor, Phase 2b in lichen planus initiated), ATI-9494 (ITK inhibitor, IND filing expected Q4 2026), and ATI-052 (anti-TSLP/IL-4R bispecific, Phase 2b in eosinophilic esophagitis planned Q1 2027). No specific dollar impact or financial terms disclosed.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
Summit Therapeutics Inc.
On November 15, 2026, the FDA issued a Complete Response Letter (CRL) for Summit's ivonescimab BLA in EGFR-mutated NSCLC, stating that substantial evidence of effectiveness is not established due to failure to achieve statistically significant overall survival (OS) improvement in the primary analysis, despite meeting the progression-free survival (PFS) primary endpoint. The HARMONi Phase III study showed ivonescimab + chemotherapy demonstrated positive OS trends and OS benefits in post-hoc regional analyses (HR 0.76), but these did not meet the FDA's regulatory threshold; the company continues development across five Phase III programs and multiple collaborative trials despite this setback.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
Nine Energy Service, Inc.
Nine Energy Service, Inc. (market cap ~$28.4M) is acquiring all membership interests in American Cementing LLC from APE IV Cementing and individual sellers. Total consideration: $7,000,000 cash plus 3,930,000 shares of Nine Energy common stock (fixed, not adjusted). Cash purchase price subject to working capital and other post-closing adjustments. Deal valued at approximately $10M+ in total consideration relative to company size.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Aramark
Aramark reported fiscal 2026 revenue of $20.1B (+9% YoY, +10% organic), with record annualized gross new business of $1.9B (>10% of prior revenue) and 97% client retention. Adjusted Operating Income grew 13% to $1.11B; Adjusted EPS increased 21% to $2.23. The Board authorized a new $1B share repurchase program (replacing $500M prior authorization) and raised the quarterly dividend by 17% to $0.14/share. Net Debt/Covenant Adjusted EBITDA improved to 2.7x (down from 3.25x), with $225M net debt reduction. FY2027 guidance: organic revenue growth 9–10%, Adjusted Operating Income growth 15–19%, Adjusted EPS growth 20–25% (all constant currency), leverage at or below 2.7x.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Blackstone Digital Infrastructure Trust Inc.
On November 11, 2026, Amazon Data Services (AWS) and Blackstone Digital Infrastructure Trust (BXDC) entered a contribution agreement establishing two 50/50 joint ventures for two data center properties (SBN and JAN). AWS contributes both properties; BXDC contributes capital. AWS receives a one-time special distribution of approximately $4.33B at closing (comprising BXDC's capital contribution plus AWS's share of debt proceeds, net of closing costs). The structure includes non-recourse financing from BXDC's debt commitment letter and long-term triple-net leases to AWS.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
BLACK HILLS CORP /SD/
Black Hills Corporation completed its all-stock merger with NorthWestern Energy Group on November 13–16, 2026, creating Bright Horizon Energy Corporation (NYSE: HZN). NorthWestern shareholders received 0.98 shares of Bright Horizon Energy per share held; Black Hills shareholders' shares now trade under the new ticker. The combined company serves 2.2 million electric and natural gas customers across eight states. Key executives Kimberly Nooney (Chief Integration Officer) and Sarah Wiltse (Chief Human Resources Officer) received transition agreements guaranteeing 2-year compensation protection and Good Reason termination rights. The company name changed effective November 13, 2026 at 10:59 p.m. Central Time.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Blackstone Digital Infrastructure Trust Inc.
Blackstone Digital Infrastructure Trust (BXDC) agreed to acquire a 75% controlling interest in 13 newly constructed data centers (647 MW across two campuses in Northern Indiana) from Amazon in a triple-net lease sale-leaseback. The aggregate gross value is $5.0B at a 7.0% initial cap rate with 2.75% annual rent escalators, 12-year initial lease term (32 years fully extended), and Amazon's parent company rated S&P AA. This is BXDC's inaugural major acquisition since its May 15, 2026 IPO.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Elauwit Connection, Inc.
Elauwit reported Q3 2026 monthly recurring revenue of $539K (up 66% YoY from $325K); billed units reached 25,746 (up 140% YoY); contracted units stood at 46,955 (up 43% YoY); backlog expanded to $53.5M from $30.3M YoY; deferred revenue grew to $9.0M from $3.6M at year-start. Total Q3 revenue was $5.6M (up 104% sequentially, 17% YoY); recurring service revenue was $1.5M (up 86% YoY). Cash position improved to $2.7M from $1.2M at June 30. Company remains unprofitable: net loss of $2.6M in Q3 (vs. $639K loss in Q3 2025).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Lexeo Therapeutics, Inc.
Lexeo reported interim Phase I/II data for LX2020 in PKP2-ACM: 7 high-dose participants achieved 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and 44% mean reduction in premature ventricular contractions (PVCs) at latest assessment (data cutoff October 15, 2026); drug was generally well tolerated with no clinically significant complement activation and no study discontinuations. FDA confirmed openness to guideline-defined NSVT as a primary endpoint for accelerated approval. Pivotal study design finalization expected H1 2027; initiation targeted H2 2027. Cash position: $219.1M as of September 30, 2026, expected to fund operations into 2028.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
InMed Pharmaceuticals Inc.
On November 6, 2026, Mentari Therapeutics (pre-merger) completed a reverse recapitalization merger with InMed Pharmaceuticals Inc., with InMed assuming Mentari's name and leadership. Immediately prior to closing, Mentari raised $490M gross ($290M + $200M in two tranches) from investors via preferred stock and pre-funded warrants at $1.8928 and $2.8923 per share respectively, including $52.7M principal+accrued interest conversion of Mentari's $50M convertible note to Fairmount. Post-merger, former Mentari shareholders own ~99% of combined company on fully diluted basis; former InMed shareholders own ~1%. The combined company retains Mentari's migraine-focused pipeline (MT-001 through MT-005 antibodies).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
AirJoule Technologies Corp.
AirJoule (NASDAQ: AIRJ, market cap $133.2M) completed acquisition of BitSink on September 10, 2026, for $18M cash + $9M stock upfront, plus up to $40M earnout in stock tied to 2027 ($30M) and 2028 ($63.6M) revenue milestones. BitSink brings $15M signed purchase orders, 220 MW deployed cooling/power equipment, 65,000 sq ft South Carolina manufacturing facility, ~40% gross margins, and 99% uptime. Company guides 2027 BitSink revenue of $15-20M with neutral-to-positive free cash flow; first AirJoule Prime system delivered to Data4 in France; Kubota partnership commenced for residential water generation.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Xtant Medical Holdings, Inc.
Xtant Medical reported Q3 2026 revenue of $24.3M (down 27% from $33.3M in Q3 2025), marking the second consecutive quarter missing guidance. The board announced an active strategic review evaluating operational improvements, partnerships, restructuring, M&A, divestitures, and financing alternatives—with no timetable set. The company withdrew full-year 2026 guidance. Core biologics grew 13% YoY to $19.3M, but gross margin compressed 970 basis points YoY to 56.3% due to lost wound-care licensing revenue ($5.5M absent) and mix shift. Cash declined to $7.8M from $17.1M; total debt is $22M. The company expects 12+ months of runway.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
CYPHERPUNK TECHNOLOGIES INC.
On August 17, 2026, Cypherpunk acquired Zcash mining equipment and hosting agreements from Moria Mining (Winklevoss affiliate) for $33.33M, paid via pre-funded warrant to WTI for 43.29M shares at $0.001/share. In 44 days (Aug 18–Sep 30), the fleet mined 8,967.29 ZEC ($9.9M revenue at $1,105/ZEC average) with 95% uptime, expanding treasury to 341,858.75 ZEC (2.01% of supply). Company plans $30M additional equipment purchase and targets 25% of Zcash network hashrate.
▲ Likely positive
· significance 72 · 8-K Agent
10-Q
Venu Holding Corp
Venu Holding Corp entered a binding term sheet dated August 16, 2026, to purchase 50% membership interest in Hipgnosis Artist Holdings LLC (HAH) and 50% interest in Welcome to the Machine LLC (WTTM) from sole owner Merck Mercuriadis for $55M total: $3.25M cash paid by August 17, 2026, plus a $51.75M non-interest-bearing promissory note due 90 days after a qualifying $200M+ funding event. Venu receives 50% distributions, one board seat, and full governance rights; units serve as collateral with forfeiture mechanics if payment defaults. Owner must contribute $10M non-dilutively to HAH by maturity date.
▲ Likely positive
· significance 72 · Periodic Agent
8-K
Larimar Therapeutics, Inc.
Larimar submitted a rolling Biologics License Application (BLA) to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia (FA) in adults and pediatric patients, using skin frataxin (FXN) as a novel surrogate endpoint. The company has $128.7M in cash (runway into late Q2 2027), reported Q3 2026 net loss of $31.1M ($0.29/share), and projects potential U.S. approval in mid-2027 with Q3 2027 launch if approved; Phase 3 FORWARD-FA trial continues enrolling.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Xtend AI Robotics, Inc.
XTEND AI Robotics completed a business combination with JFB Construction Holdings on September 3, 2026, raising $110M total capital. Q3 2026 revenue reached $14.9M (up 281% YoY); AI Robotics segment alone grew 230% to $12.9M. Funded backlog grew to $100.7M as of November 16 (from $12.4M at year-end 2025). The company received a $40.5M order for 6,000 STRIKER systems and advanced to Phase III in SOCOM's modular drone program. Post-quarter-end orders added $10.65M (EMEA $2.35M + APAC $8.3M). However, net loss was $44.6M in Q3 (vs. $5.3M in Q3 2025), including $13.5M in one-time public company costs and $11.1M stock-based compensation.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
MapLight Therapeutics, Inc.
MapLight Therapeutics reported positive Phase 2 ZEPHYR trial results for ML-007C-MA (210/3 mg BID) in schizophrenia, meeting its primary endpoint with PANSS total score reduction of 4.5 points vs. placebo (effect size 0.37, p=0.015; 0.50 in completers). The company raised $150M in August 2026 and ended Q3 2026 with $463.4M cash, sufficient to fund operations through 2028, including planned Phase 3 ZEPHYR-2 trial (topline 2H 2027) and ongoing Phase 2 VISTA trial in Alzheimer's disease psychosis (topline 2028). ML-007C-MA also showed prespecified cognitive benefit (effect size 0.51, p=0.041) and was well-tolerated with 99% reaching target dose and low GI discontinuations (2%), contrasting favorably with Cobenfy's safety profile.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Moleculin Biotech, Inc.
Moleculin Biotech (market cap ~$8.8M) completed treatment of all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for relapsed/refractory AML, with comprehensive data readout expected Q1 2027. The company reported Q3 2026 net loss of $6.5M (vs. $25.4M in Q3 2025), with cash position declining to $7.3M as of September 30, 2026, from $8.9M at year-end 2025. A peer-reviewed cardiac safety analysis of 90 patients across five trials showed no clinical or subclinical cardiotoxicity, and preclinical data suggest Annamycin may enhance immune response in pancreatic cancer models.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Medicus Pharma Ltd.
On November 13, 2026, Medicus Pharma Ltd. (Ontario) completed two concurrent transactions: (1) a registered offering of 97,973 common shares and 1,646,213 pre-funded warrants (exercisable for 1,646,213 common shares at $0.0001 per share) at $1.72 per share equivalent under Securities Purchase Agreement; (2) an exchange of a $10.5M partitioned portion of a $12.864M secured note (originally issued May 27, 2026 to Streeterville Capital LLC) for 105,000 preferred shares under Section 3(a)(9) exemption. The note balance reduced from $12.864M to $2.904M post-exchange. No specific dollar total raised disclosed for the equity offering; note conversion valued at $10.5M. Total dilution from both transactions not quantified in filings.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
CREATIVE REALITIES, INC.
Creative Realities reported Q3 2026 revenue of $26.2M vs. $10.5M prior year, with gross profit of $9.7M (37.1% margin). ARR grew to $21.7M from $12.3M YoY. Major customer wins include Zaxby's (1,000+ locations converted to Clarity CMS) and Albertsons (500+ stores deployed, 30M+ ads daily). Debt reduced $4M to $40M outstanding. CEO projects FY2026 revenue exceeding $100M, with Tennessee Titans stadium installation underway for completion by year-end.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Montauk Renewables, Inc.
Montauk reported Q3 2026 revenues of $50.2M (+10.9% YoY) but net income fell 58.9% to $2.1M; Adjusted EBITDA declined 20.6% to $10.2M. The company executed a non-binding term sheet with lenders for debt amendment and covenant forbearance, averting previously anticipated going-concern qualification. Turkey, North Carolina facility began power generation but requires ~$15M in enhancements for moisture control and syngas temperature preservation. Cash declined to $12.4M from $23.8M year-end 2025; long-term debt rose to $149.7M. Without lender relief, company expects covenant default by December 31, 2026.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
Surgery Partners, Inc.
Surgery Partners' subsidiary Surgery Center Holdings is soliciting consent from holders of $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032 to amend the indenture governing those notes. The proposed amendments would designate Bon Secours Mercy Health (BSMH) and affiliates as Permitted Holders under the indenture to avoid triggering a Change of Control offer requirement upon completion of the merger with BSMH (expected Q1 2027). Consenting holders receive a $2.50 per $1,000 principal Consent Fee if requisite majority consent is obtained and conditions satisfied; consent solicitation expires November 20, 2026 at 5:00 p.m. ET.
— Neutral
· significance 72 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.